ScreenerHero

ALVOAlvotech Ordinary Shares

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · alvotech.com
4.430USDMkt Cap: 1.50B $P/E: —

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap1.50B $
Enterprise Value2.89B $
Revenue (TTM)494.61M $
Gross Profit350.76M $
Net Income (TTM)27.92M $
Revenue/Share1.675 USD
Last Price4.430 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.3K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)19.65
PEG—
EV/EBITDA38.16
EV/Revenue5.84
P/S3.03
P/B-4.86
EPS (TTM)-0.62
EPS (Forward)0.23
52W Range
4.32040% of range4.595
52W High4.595 USD
52W Low4.320 USD
Profitability
Gross Margin59.82%
Oper. Margin-11.05%
EBITDA Margin15.31%
Profit Margin4.76%
ROE-9.81%
ROA1.88%
Growth
Revenue Growth-38.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.20M $
CapEx (TTM)96.13M $
FCF Margin-24.89%
FCF Yield-8.22%
Net Debt1.31B $
Net Debt/EBITDA17.28
Balance Sheet
Debt/Equity-5.09
Current Ratio1.65
Quick Ratio0.79
Book Value/Sh-0.9120 USD
Cash/Share0.4000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)5.750 USD
Upside (mean)+29.8%
Target Range4.000 USD – 9.000 USD
$4.000+29.8% to mean$9.000
# Analysts4
Ownership
Shares Out.338.22M
Float140.79M
Insiders54.54%
Institutions11.63%
Short Interest
Short Ratio5.9d
Short % Float3.24%
Short % Out.1.36%
Shares Short4.61M
Short (prev mo.)2.92M
Technical
SMA 503.680 (+20.4%)
SMA 2004.158 (+6.5%)
Beta0.18
S&P 52W Chg19.18%
Avg Vol (30d)2.27M
Avg Vol (10d)933.69K
Technical Indicators
RSI (14)68.9
MACD0.1813
MACD Signal0.1295
MACD Hist.+0.0519
BB Upper4.497 USD
BB Middle3.832 USD
BB Lower3.168 USD
BB Width34.67%
ATR (14)0.2478 USD
Vol Ratio (20d)2.62x